Search

Displaying results 4951 - 4960 of 10000 in total
  1. Drug

    Bethanidine

    go.drugbank.com/drugs/DB00217
    Approved

    A guanidinium antihypertensive agent that acts by blocking adrenergic transmission.

  2. Drug

    Ancriviroc

    go.drugbank.com/drugs/DB19773
    Experimental

    Ancriviroc has a monoisotopic molecular weight of 556.2 Da. … Ancriviroc is a small molecule drug. The usage of the INN stem '-viroc' in the name indicates that Ancriviroc is a CCR5 (Chemokine CC motif receptor 5) receptor antagonist.

  3. Drug

    Xemilofiban

    go.drugbank.com/drugs/DB21058
    Experimental

    Xemilofiban has a monoisotopic molecular weight of 358.16 Da. … Xemilofiban is a small molecule drug. The usage of the INN stem '-fiban' in the name indicates that Xemilofiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist).

  4. Drug

    Amdizalisib

    go.drugbank.com/drugs/DB21514
    Investigational

    Amdizalisib has a monoisotopic molecular weight of 390.11 Da. … Amdizalisib is a small molecule drug.

  5. Drug

    Inaxaplin

    go.drugbank.com/drugs/DB21521
    Investigational

    Inaxaplin has a monoisotopic molecular weight of 417.13 Da. … Inaxaplin is a small molecule drug.

  6. Drug

    Imdatifan

    go.drugbank.com/drugs/DB21643
    Experimental

    Imdatifan has a monoisotopic molecular weight of 385.05 Da. … Imdatifan is a small molecule drug. The usage of the INN stem '-tifan' in the name indicates that Imdatifan is a hypoxia inducible factor (HIF)-2alpha (HIF-2a) inhibitor.

  7. Drug

    Chromic citrate

    go.drugbank.com/drugs/DB14526
    Experimental

  8. Drug

    Fosdenopterin

    go.drugbank.com/drugs/DB16628
    Approved

    [A230088] Signs and symptoms begin shortly after birth and are caused by a build-up of toxic sulfites resulting from a lack of SOX activity. … In 2009 a recombinant, E. coli-produced cPMP was granted orphan drug designation by the FDA, becoming the first therapeutic option for patients with MoCD type A.

  9. Drug

    Selexipag

    go.drugbank.com/drugs/DB11362
    ApprovedInvestigational

    PAH is a relatively rare disease with usually a poor prognosis requiring more treatment options to prolong long-term outcomes. … Marketed by Actelion Pharmaceuticals under brand name Uptravi, selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to increase vasodilation in the pulmonary

  10. Drug

    Phenindamine

    go.drugbank.com/drugs/DB01619
    Approved

    Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. … Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells.